Allam was serving recently as the CEO at Public Investment Fund
None of the observations are related to data integrity and management believes that they are addressable
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors
Global pharmaceutical company having a surgical business concept incepted in Dubai
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Subscribe To Our Newsletter & Stay Updated